The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...

As of today, three other GLP-1 receptor agonists remain on the FDA's shortage list: semaglutide (Ozempic, Wegovy), ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

The U.S. Food and Drug Administration on Thursday found that there was no longer a shortage of Eli Lilly's blockbuster weight ...

Eli Lilly & Co.’s weight-loss and diabetes drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...

Memory-chip maker swung to a profit and posted higher revenue in its fiscal first quarter, though shares fell after the company's outlook missed estimates. CVS ignored substantial evidence from ...

A promising new compound, HPH-15, may represent a significant breakthrough ... Compared to the widely used diabetes drug ...

The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity ... Hers Health fell by about 10% in Thursday trading on news ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...